-+ 0.00%
-+ 0.00%
-+ 0.00%

bioAffinity says CyPath Lung test sales more than double through Q3 2026

PUBT·10/06/2026 13:19:19
Listen to the news
bioAffinity says CyPath Lung test sales more than double through Q3 2026
  • bioAffinity Technologies reported CyPath Lung test sales rose more than 100% through Q3 2026 versus the prior-year period.
  • Ordering physicians increased 89% in Q3 versus Q3 2025.
  • Physicians who ordered through Q3 2025 lifted test volume 48% year over year.
  • Delivered 1,620 tests through Q3 versus 775 a year earlier.
  • Distribution agreement with Veteran-Owned AvMEDICAL targets broader access in government healthcare, including the Department of Veterans Affairs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261006386482) on October 06, 2026, and is solely responsible for the information contained therein.